CDH17 胃癌细胞治疗获得美国食品与药物管理局的孤儿药物地位。 Chimeric Therapeutics gets FDA orphan drug status for its CDH17 cell therapy in gastric cancer.

摇头丸治疗机构因其以胃癌为对象的CHM CDH17细胞治疗、给予发展奖励和潜在的市场排他性而获得美国药管局的孤儿药品称号。 Chimeric Therapeutics received FDA Orphan Drug Designation for its CHM CDH17 cell therapy targeting gastric cancer, granting development incentives and potential market exclusivity. 该疗法针对固态肿瘤中CDH17蛋白质,目前处于前直肠和胃癌试验第1/2阶段,迄今已有9名病人接受治疗。 The therapy, aimed at the CDH17 protein in solid tumors, is in a Phase 1/2 trial for advanced colorectal and gastric cancers, with nine patients treated so far. 伊穆格因还获得了FDA对其现成的CAR T细胞治疗azer-cel的支持,证实了其针对扩散型大B细胞淋巴瘤的临床途径和剂量策略. Imugene also received FDA support for its off-the-shelf CAR T-cell therapy azer-cel, confirming its clinical pathway and dosing strategy for diffuse large B-cell lymphoma. 与此同时,Kairos Minerals公司与Nyamal土著公司签订了采矿协议,在西澳大利亚开展Mt York黄金项目,Lindian Resources开始在马拉维的Kangankunde稀土项目中钻探,以评估高等级的Nudmium-praseyum地区。 Meanwhile, Kairos Minerals secured a mining agreement with the Nyamal Aboriginal Corporation for its Mt York Gold Project in Western Australia, and Lindian Resources began drilling at its Kangankunde rare earths project in Malawi to assess high-grade neodymium-praseodymium zones.